Helen Tayton-Martin
2020
In 2020, Helen Tayton-Martin earned a total compensation of $1.6M as Chief Business Officer at Adaptimmune Therapeutics, a 15% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $223,186 |
|---|---|
| Option Awards | $857,661 |
| Salary | $450,881 |
| Other | $23,321 |
| Total | $1,555,050 |
Tayton-Martin received $857.7K in option awards, accounting for 55% of the total pay in 2020.
Tayton-Martin also received $223.2K in non-equity incentive plan, $450.9K in salary and $23.3K in other compensation.
Rankings
In 2020, Helen Tayton-Martin's compensation ranked 6,681st out of 13,090 executives tracked by ExecPay. In other words, Tayton-Martin earned more than 49.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,681 out of 13,090 | 49th |
Division Manufacturing | 2,775 out of 5,621 | 51st |
Major group Chemicals And Allied Products | 1,121 out of 2,254 | 50th |
Industry group Drugs | 967 out of 1,954 | 51st |
Industry Biological Products, Except Diagnostic Substances | 229 out of 411 | 44th |
Source: SEC filing on April 21, 2022.
Tayton-Martin's colleagues
We found four more compensation records of executives who worked with Helen Tayton-Martin at Adaptimmune Therapeutics in 2020.